Swiss stocks – Factors to watch on Oct 21

ZURICH, Oct 21 (BestGrowthStock) – Swiss shares are set to slip on
Thursday after index-heavy weight Credit Suisse reported
disappointing third-quarter results.

The Swiss blue-chip index SMI(.SSMI: ) was indicated to slip
12 points to 6466, premarket data provided by bank Clariden Leu
showed.(CLPRE: )

Shares in Credit Suisse were indicated to open down 2.8
percent (CLPRE2: ).

The following are some of the main factors expected to
affect Swiss stocks on Thursday:

CREDIT SUISSE (CSGN.VX: )

Net profit at Swiss bank Credit Suisse (CSGN.VX: )(CS.N: ) fell
74 percent in the third quarter, as sluggish equities trading
ate into investment banking earnings.

For related news, click on [CSGN.VX]]

NOVARTIS (NOVN.VX: )

Novartis stuck to its full-year sales guidance after posting
a better-than-expected 16 percent rise in third-quarter core
earnings thanks to strong demand for recently launched drugs.

Eye care products maker Alcon Inc (ACL.N: ), which Swiss
drugmaker Novartis is buying, reported a 13 percent drop in
quarterly profit as merger costs offset sales growth in product
areas such as implanted lenses and glaucoma drugs.

For related news, click on [NOVN.VX]

ACTELION (ATLN.VX: )

Actelion Ltd (ATLN.VX: ) announced an 800 million Swiss franc
share buyback after its third-quarter profit (Read more your timing to make a profit.) fell, reacting to
increased shareholder pressure following a number of product
setbacks.

For related news, click on [ATLN.VX]

SYNTHES (SYST.VX: )

Swiss medical device maker Synthes Inc (SYST.VX: ) gave a
cautious outlook for the coming months on Thursday after posting
a weaker-than expected rise in third-quarter sales.

For related news, click on [SYST.VX]

ROCHE (ROG.VX: )

Roche Holding AG’s cancer drug Herceptin has been approved,
in combination with chemotherapy, by U.S. regulators as a
treatment for patients with HER2-positive metastatic stomach
cancer, the company’s Genentech unit said on Wednesday.

ECONOMY [M-CH]

* Swiss trade data for September is due at 0615 GMT (ECONCH: )

* The Swiss National Bank will is publishing its monthly
statistical bulletin at 0700 GMT

COMPANY STATEMENTS [CNR-CH]

* OC Oerlikon (OERL.S: ) reports 9-month order intake of 3.2
billion Swiss francs [OERL.S]

* Cytos (CYTN.S: ): National Institutes of Health, SAIC, and
Cytos Biotechnology Collaborate onMalaria Vaccines Research

* INFICON Achieves Very Good Results in the Third Quarter
2010 (IFCN.S: )

EQUITY RESEARCH [CH-RCH]

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

(.EX.S: ) for all Swiss stocks

(.EXSMI.S: ) for blue chips

(.EXNSMI.S: ) for other stocks

Swiss stocks – Factors to watch on Oct 21